Defining the risk of SARS-CoV-2 variants on immune protection
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
The germinal centre B cell response to SARS-CoV-2
BJ Laidlaw, AH Ellebedy - Nature Reviews Immunology, 2022 - nature.com
The germinal centre (GC) response is critical for the generation of affinity-matured plasma
cells and memory B cells capable of mediating long-term protective immunity …
cells and memory B cells capable of mediating long-term protective immunity …
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
highlighted the need for vaccines that not only prevent disease but also prevent …
highlighted the need for vaccines that not only prevent disease but also prevent …
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
The emerging SARS-CoV-2 variants of concern (VOCs) threaten the effectiveness of current
COVID-19 vaccines administered intramuscularly and designed to only target the spike …
COVID-19 vaccines administered intramuscularly and designed to only target the spike …
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
Intranasal COVID-19 vaccines: From bench to bed
A Alu, L Chen, H Lei, Y Wei, X Tian, X Wei - EBioMedicine, 2022 - thelancet.com
Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization.
However, vaccination today failed to prevent the virus infection through the upper respiratory …
However, vaccination today failed to prevent the virus infection through the upper respiratory …
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases,
and their ability to induce a potent and balanced immune response made them logical …
and their ability to induce a potent and balanced immune response made them logical …
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
N van Doremalen, JN Purushotham… - Science translational …, 2021 - science.org
ChAdOx1 nCoV-19/AZD1222 is an approved adenovirus-based vaccine for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being deployed globally …
respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being deployed globally …
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
D Lapuente, J Fuchs, J Willar, A Vieira Antão… - Nature …, 2021 - nature.com
Several effective SARS-CoV-2 vaccines are currently in use, but effective boosters are
needed to maintain or increase immunity due to waning responses and the emergence of …
needed to maintain or increase immunity due to waning responses and the emergence of …
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters
Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the
pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV …
pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV …